Bio

Clinical Focus


  • Pediatrics
  • Oncology

Academic Appointments


Administrative Appointments


  • Division Chief, Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine (2020 - Present)
  • Director, Bass Center for Childhood Cancer and Blood Diseases, Lucile Packard Children’s Hospital, Stanford (2020 - Present)
  • Associate Director, Childhood Cancer, Stanford Cancer Institute (2020 - Present)

Professional Education


  • Fellowship: Childrens Hospital Los Angeles Hematology Oncology Fellowship (2009) CA
  • Residency: Children's Hospital Los Angeles Pediatric Residency (2006) CA
  • Medical Education: University of Southern California (2003) CA
  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2001)

Teaching

2020-21 Courses


Publications

All Publications


  • The genomic landscape of juvenile myelomonocytic leukemia NATURE GENETICS Stieglitz, E., Taylor-Weiner, A. N., Chang, T. Y., Gelston, L. C., Wang, Y., Mazor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S. R., Rosenberg, M., Archambeault, S. L., Abusin, G., Beckman, K., Brown, P. A., Briones, M., Carcamo, B., Cooper, T., Dahl, G. V., Emanuel, P. D., Fluchel, M. N., Goyal, R. K., Hayashi, R. J., Hitzler, J., Hugge, C., Liu, Y. L., Messinger, Y. H., Mahoney, D. H., Monteleone, P., Nemecek, E. R., Roehrs, P. A., Schore, R. J., Stine, K. C., Takemoto, C. M., Toretsky, J. A., Costello, J. F., Olshen, A. B., Stewart, C., Li, Y., Ma, J., Gerbing, R. B., Alonzo, T. A., Getz, G., Gruber, T. A., Golub, T. R., Stegmaier, K., Loh, M. L. 2015; 47 (11): 1326-?

    Abstract

    Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 or CBL occur in 85% of patients, yet there are currently no risk stratification algorithms capable of predicting which patients will be refractory to conventional treatment and could therefore be candidates for experimental therapies. In addition, few molecular pathways aside from the RAS-MAPK pathway have been identified that could serve as the basis for such novel therapeutic strategies. We therefore sought to genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML. We identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription. Notably, the number of somatic alterations present at diagnosis appears to be the major determinant of outcome.

    View details for DOI 10.1038/ng.3400

    View details for PubMedID 26457647

Latest information on COVID-19